Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Research Coverage on Small and Micro-Cap Companies

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Equity Bottom-Up

<ul><li>Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using oral and topical delivery.</li><li>It combines lipophilic APIs with specific fatty acid and carrier compounds followed by dehydration.</li><li>DHT offers several attractive features: substantial improvement in bioabsorption in terms of time to measurable plasma levels & AUC, brain permeation, taste masking & side effect reduction.</li></ul>

Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using oral and topical delivery.It combines lipophilic APIs with specific fatty acid and carrier compounds followed by dehydration.DHT offers several attractive features: substantial improvement in bioabsorption in terms of time to measurable plasma levels & AUC, brain permeation, taste masking & side effect reduction.

LEXX: IRB Approval Clears Way for GLP-1 Study #5

<ul><li>Zacks Small-Cap Research Note for Lexaria Bioscience Corp. (LEXX)</li></ul>

Zacks Small-Cap Research Note for Lexaria Bioscience Corp. (LEXX)

LEXX: Changing Gears: Christopher Takes Over as CEO

Canada

Lexaria Bioscience Corp improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods. The Company's technology can be applied to ingestible product formats such as foods, beverages, oral suspensions, tablets, and capsules. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Lexaria Bioscience (LEXX US)

LEXX: IRB Approval Clears Way for GLP-1 Study #5

Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using...

Zacks Small Cap Research

LEXX: Phase I Start Imminent

Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using...

Zacks Small Cap Research

LEXX: Changing Gears: Christopher Takes Over as CEO

Zacks Small-Cap Research Note for Lexaria Bioscience Corp. (LEXX)

Zacks Small Cap Research

LEXX: GLP-1 Agonist Program Updates

Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using...

Zacks Small Cap Research

LEXX: Begin with the End in Mind

Lexaria is a biotechnology company seeking to enhance the bioavailability of multiple drug agents using DehydraTECH (DHT), its technology using...

Zacks Small Cap Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)